NMR based metabonomics study of NPY Y5 receptor activation in BT-549, a human breast carcinoma cell line

[1]  J. Baumbach,et al.  Heterogeneity in tumor cell energetic metabolome at different cell cycle phases of human colon cancer cell lines , 2011, Metabolomics.

[2]  T. Ramelot,et al.  NMR Based Metabonomics Study of DAG Treatment in a C2C12 Mouse Skeletal Muscle Cell Line Myotube Model of Burn-Injury , 2011, International Journal of Peptide Research and Therapeutics.

[3]  Lei Zhang,et al.  The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer. , 2011, Pharmacology & therapeutics.

[4]  N. Bouchemal,et al.  Metabolomic profiling with NMR discriminates between biphosphonate and doxorubicin effects on B16 melanoma cells , 2010, NMR in biomedicine.

[5]  Jens O Krömer,et al.  Towards quantitative metabolomics of mammalian cells: development of a metabolite extraction protocol. , 2010, Analytical biochemistry.

[6]  Aaron M. Goodpaster,et al.  Statistical significance analysis of nuclear magnetic resonance-based metabonomics data. , 2010, Analytical biochemistry.

[7]  K. Haider,et al.  Neuropeptide Y Y5 Receptor Promotes Cell Growth through Extracellular Signal-Regulated Kinase Signaling and Cyclic AMP Inhibition in a Human Breast Cancer Cell Line , 2010, Molecular Cancer Research.

[8]  Michael A Kennedy,et al.  NMR‐based metabonomics analysis of mouse urine and fecal extracts following oral treatment with the broad‐spectrum antibiotic enrofloxacin (Baytril) , 2009, Magnetic resonance in chemistry : MRC.

[9]  S. Fox,et al.  No evidence for promoter region methylation of the succinate dehydrogenase and fumarate hydratase tumour suppressor genes in breast cancer. , 2009 .

[10]  O. Feron,et al.  Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  G. Bai,et al.  NMR metabolomic analysis of caco-2 cell differentiation. , 2009, Journal of proteome research.

[12]  A. M. Gil,et al.  Analytical approaches toward successful human cell metabolome studies by NMR spectroscopy. , 2009, Analytical chemistry.

[13]  G. Semenza,et al.  Uterine DCs are essential for pregnancy. , 2008, The Journal of clinical investigation.

[14]  A. Lane,et al.  Targeting aspartate aminotransferase in breast cancer , 2008, Breast Cancer Research.

[15]  D. Brougham,et al.  Metabolomic studies of human lung carcinoma cell lines using in vitro 1H NMR of whole cells and cellular extracts , 2008, NMR in biomedicine.

[16]  Ralph J Deberardinis,et al.  Brick by brick: metabolism and tumor cell growth. , 2008, Current opinion in genetics & development.

[17]  Balázs Papp,et al.  Evaluation of predicted network modules in yeast metabolism using NMR-based metabolite profiling. , 2007, Genome research.

[18]  J. Reubi,et al.  NPY receptors in human cancer: A review of current knowledge , 2007, Peptides.

[19]  V. Ganapathy,et al.  SLC5A8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases. , 2006, Cancer research.

[20]  E. Gottlieb,et al.  Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer , 2006, Oncogene.

[21]  Calum MacAulay,et al.  A Phase I Study of myo-Inositol for Lung Cancer Chemoprevention , 2006, Cancer Epidemiology Biomarkers & Prevention.

[22]  Robert Powers,et al.  NMR metabolic profiling of Aspergillus nidulans to monitor drug and protein activity. , 2006, Journal of proteome research.

[23]  S. Sheriff,et al.  Estrogen up-regulates neuropeptide Y Y1 receptor expression in a human breast cancer cell line. , 2006, Cancer research.

[24]  L. Tretter,et al.  Alpha-ketoglutarate dehydrogenase: a target and generator of oxidative stress , 2005, Philosophical Transactions of the Royal Society B: Biological Sciences.

[25]  J. Reubi,et al.  Neuropeptide Y receptors in renal cell carcinomas and nephroblastomas , 2005, International journal of cancer.

[26]  Jason U Tilan,et al.  Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors. , 2005, Cancer research.

[27]  K. Chung,et al.  Neuropeptide Y (NPY). , 2004, Pulmonary pharmacology & therapeutics.

[28]  B. Chronwall,et al.  Neuropeptide Y, ubiquitous and elusive , 2004, Peptides.

[29]  Rodrigue Rossignol,et al.  Energy Substrate Modulates Mitochondrial Structure and Oxidative Capacity in Cancer Cells , 2004, Cancer Research.

[30]  Michael J Thun,et al.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.

[31]  J. Nicholson,et al.  NMR and pattern recognition studies on liver extracts and intact livers from rats treated with alpha-naphthylisothiocyanate. , 2002, Biochemical pharmacology.

[32]  S. Williams,et al.  A comparison of cell and tissue extraction techniques using high‐resolution 1H‐NMR spectroscopy , 2002, NMR in biomedicine.

[33]  J C Reubi,et al.  Y(1)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. , 2001, Cancer research.

[34]  M J Welch,et al.  Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. , 2001, Nuclear medicine and biology.

[35]  V. Steele,et al.  Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol. , 2000, Carcinogenesis.

[36]  D. Mcfadden,et al.  Peptide YY inhibits growth of human breast cancer in vitro and in vivo. , 1999, The Journal of surgical research.

[37]  John T. Clark,et al.  Neuropeptide Y (NPY) levels in alcoholic and food restricted male rats: implications for site selective function , 1998, Regulatory Peptides.

[38]  A. Balasubramaniam.  Neuropeptide Y Family of Hormones: Receptor Subtypes and Antagonists , 1997, Peptides.

[39]  R. Estensen,et al.  Chemopreventive effects of myo-inositol and dexamethasone on benzo[a]pyrene and 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone-induced pulmonary carcinogenesis in female A/J mice. , 1996, Cancer research.

[40]  R. Estensen,et al.  Studies of chemopreventive effects of myo-inositol on benzo[a]pyrene-induced neoplasia of the lung and forestomach of female A/J mice. , 1993, Carcinogenesis.

[41]  J. Wharton,et al.  Expression of the human neuropeptide tyrosine Y1 receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[42]  E. Newsholme,et al.  Maximum activities of key enzymes of glycolysis, glutaminolysis, pentose phosphate pathway and tricarboxylic acid cycle in normal, neoplastic and suppressed cells. , 1990, The Biochemical journal.

[43]  A. Lehninger,et al.  The pathways of glutamate and glutamine oxidation by tumor cell mitochondria. Role of mitochondrial NAD(P)+-dependent malic enzyme. , 1984, The Journal of biological chemistry.

[44]  R. Orlando,et al.  Multiple molecular forms of lactate dehydrogenase and glucose 6‐phosphate dehydrogenase in normal and abnormal human breast tissues , 1976, Cancer.

[45]  S. Sheriff,et al.  Estrogen Upregulates Neuropeptide Y Y 1 Receptor Expression in a Human Breast Cancer Cell Line , 2006 .

[46]  Eyal Gottlieb,et al.  Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. , 2005, Cancer cell.

[47]  David G. Watson,et al.  Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. , 2005, Cancer cell.

[48]  G. Scambia,et al.  Estrogen responsive creatine kinase in human breast cancer cells , 2004, Journal of Cancer Research and Clinical Oncology.

[49]  J. Polak,et al.  Expression of the human neuropeptide tyrosine Y 1 receptor ( in situ hybridization / colon / kidney / placenta / cardiovascular system ) , 2004 .

[50]  J. Reubi,et al.  Neuropeptide Y receptor expression in human primary ovarian neoplasms , 2004, Laboratory Investigation.